Type 1 diabetes is a T-cell--mediated autoimmune disease in which the insulin-producing β-cells in the pancreatic islets of Langerhans are destroyed ([@B1]--[@B3]). Studies in at-risk individuals, type 1 diabetic patients, and NOD mice have shown that the breakdown in β-cell--specific T-cell tolerance is multifactorial, leading to impaired peripheral immunoregulation ([@B1]--[@B3]). The diabetogenic response is characterized by a progressive but nondestructive infiltration of the islets by CD4^+^ and CD8^+^ effector T cells (Teffs), forkhead box p3--expressing Tregs (Foxp3^+^Tregs), and other immune effectors in NOD mice ([@B4]). This innocuous insulitis then progresses to a destructive stage, leading to β-cell depletion and clinical type 1 diabetes. Recently, it has become evident that the transition to destructive insulitis is in part due to impaired islet-resident Foxp3^+^Tregs in NOD mice ([@B5]--[@B8]).

Foxp3^+^Tregs are dependent on interleukin-2 (IL-2) for maintenance of Foxp3 gene expression, survival, proliferation, and suppressor function ([@B9]--[@B12]). However, unlike conventional T cells, Foxp3^+^Tregs do not express IL-2 and consequently are dependent on Teffs and dendritic cells as IL-2 sources ([@B12]--[@B14]). Dysregulation of the IL-2--IL-2 receptor (IL-2R) pathway contributes to the impaired Foxp3^+^Treg pool in NOD mice and type 1 diabetic patients ([@B15]--[@B17]). In NOD mice, decreased IL-2 production by Teffs and dendritic cells, a defect mapping to the insulin-dependent diabetes (*Idd3)* locus containing the *Il2* gene, correlates with reduced Foxp3^+^Treg survival ([@B15]--[@B20]). Aberrant Foxp3^+^Treg survival in NOD mice is detected only in the islets and not in the draining pancreatic lymph nodes (PLNs), a site for differentiation of pathogenic Teffs and various Treg subsets ([@B15]--[@B17]). In contrast, FOXP3^+^Tregs obtained from peripheral blood of type 1 diabetic patients exhibit deficient IL-2R signaling in vitro, evident by reduced phosphorylation of signal tranducer and activator of transcription 5 (pSTAT5), a transcription factor that regulates Foxp3^+^Treg-dependent genes ([@B21]).

In view of the potent effects of IL-2 on Foxp3^+^Tregs, recombinant (r)IL-2 therapy has garnered significant interest for the treatment of chronic inflammation, transplantation, and autoimmunity. The pleiotropic and potentially toxic effects resulting from IL-2 stimulation of conventional T cells and other immune effectors has led to systemic administration of low doses of rIL-2. Low-dose rIL-2 therapy exploits the ability of Foxp3^+^Tregs, which constitutively express CD25 and the corresponding high-affinity IL-2R, to outcompete other immune effectors when IL-2 is limiting ([@B22]). Clinical studies have shown that low-dose rIL-2 therapy is protective in graft-versus-host disease and hepatitis C virus--induced vasculitis ([@B23],[@B24]). In addition, β-cell autoimmunity is prevented and/or suppressed in NOD mice following treatment with low-dose rIL-2, rIL-2--anti--IL-2 antibody complexes, or a tetracycline-inducible adeno-associated virus (AAV) vector expressing IL-2 systemically by enhancing the Foxp3^+^Treg pool ([@B16],[@B25]--[@B29]). A recent phase I/II trial testing rIL-2 and rapamycin in type 1 diabetic patients, however, reported only a transient increase in FOXP3^+^Tregs ([@B30]), possibly reflecting the need for elevated and persistent levels of IL-2. Furthermore, treatment resulted in an increase in activated natural killer (NK) cells and eosinophils and an accelerated loss of insulin C-peptide levels, suggesting exacerbated β-cell autoimmunity. These clinical findings highlight the potential therapeutic benefit as well as the difficulty in achieving a balance between efficacy and the unwanted pleiotropic and systemic activity of IL-2.

Accordingly, we have assessed the use of AAV vectors to increase local IL-2 levels in the islets and enhance the resident Foxp3^+^Treg pool in vivo. AAV vectors are nonreplicating, noncytopathic, nonintegrating, and arguably the most effective and safe strategy to deliver genes in vivo ([@B31]). Indeed, AAV vectors have been successfully applied in the clinic to complement various genetic disorders ([@B32]--[@B34]). AAV vectors transduce both dividing and nondividing cells, and the availability of several serotypes and newly engineered vectors permit targeting of a broad range of cell types and tissues in vivo. Furthermore, selective transgene expression can be achieved with cell-specific promoters ([@B35],[@B36]). Coupled with the development of self-complementary or double stranded (ds)AAV vectors ([@B37],[@B38]), as well as the recent advances in manufacturing and purification, AAV vectors provide an approach to sustain long-term transgene expression in vivo. In the current study, we demonstrate that dsAAV vector--mediated IL-2 expression by β-cells selectively increases the frequency and function of islet Foxp3^+^Tregs to effectively suppress type 1 diabetes long-term.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Mice. {#s2}
-----

NOD/LtJ, NOD.CB17-Prkdcscid/J (NOD.*scid*), NOD.Cα^−/−^, NOD.BDC ([@B39]), NOD.BDC.Foxp3^GFP^ ([@B40]), and NOD.8.3 ([@B41]) mice were bred and maintained under specific pathogen-free conditions in an American Association for Laboratory Accreditation--accredited animal facility. NOD mice were diagnosed as diabetic after three consecutive blood glucose readings \>250 mg/dL. All procedures were approved by the University of North Carolina Animal Use and Care Committee.

dsAAV vector engineering, packaging, and vaccination. {#s3}
-----------------------------------------------------

Full-length cDNA encoding murine *Il2* (of the NOD genotype) and *EGFP* were subcloned into a dsAAV plasmid ([@B37]) containing the murine preproinsulin II promoter (mIP). dsAAV vector packaging was carried out as previously described ([@B42]). Briefly, HEK 293T cells were cotransfected via polyethyleneimine with adeno helper plasmid (pXX6--80), AAV8 capsid plasmid, and dsAAVmIP-IL2/enhanced green fluorescent protein (EGFP) plasmid. Nuclear fractions were harvested 72 h posttransfection and packaged vector purified with a Cesium Chloride (RPI Corp.) gradient. Vector containing fractions and titers were determined by Southern dot blot. NOD mice were vaccinated intraperitoneally with dsAAV8mIP-IL2 or dsAAV8mIP-EGFP.

ELISA. {#s4}
------

The anti--IL-2 antibody set (JES6-1 and JES6-5; eBioscience) was used at a concentration of 2 μg/mL on a high binding ELISA plate (Costar) to measure IL-2 levels in serum and islet cultures. Interferon-γ (IFN-γ) was measured with the mouse IFN-γ ELISA set (BD optEIA; BD Biosciences) as per the manufacturer's recommendations.

Islet isolation and streptozotocin treatment. {#s5}
---------------------------------------------

Pancreases were perfused with 2 mg/mL collagenase P (Roche) and digested for 30 min at 37°C. Islets were purified via Ficoll gradient, handpicked, and counted. For flow cytometry analysis, lymphocytes were collected from freshly isolated islets after culturing in RMPI complete medium for a minimum of 4 h at 37°C and filtered through a 70-micron nylon mesh.

NOD mice were treated intraperitoneally with 200 mg/kg of streptozotocin (STZ; Sigma-Aldrich), resuspended in fresh sodium citrate buffer (pH 4.0), and 72 h later vaccinated intraperitoneally with AAV8mIP-IL2 or left untreated. Blood glucose levels and serum IL-2 were assessed over 10 days post--rAAV vector vaccination.

Flow cytometry. {#s6}
---------------

Cells from various tissues were stained with previously titrated fluorochrome-conjugated monoclonal antibodies specific for: CD3 (145-2C11), CD4 (GK1.5), CD8 (Ly-2), CD25 (PC61.5), CD62L (MEL-14), glucocorticoid-induced tumor necrosis factor receptor--related protein (GITR, DTA-1), inducible costimulator (ICOS, 7E.17G9), cytotoxic T lymphocyte--associated antigen-4 (CTLA-4, UC10-4F10-11), and Foxp3 (FJK-16s). Fc receptors were blocked with rat anti-mouse CD16/32 (2.4G2; BD Biosciences) prior to staining. Intracellular KI67 (B56; BD Biosciences) and Bcl-2 (3F11; BD Biosciences) staining was done using the Fix/Perm and Perm/Wash reagents (eBioscience) according to the manufacturer\'s recommendations.

Intracellular cytokine staining was performed on single-cell suspensions as previously described ([@B43]). Briefly, lymphocytes were stimulated with 500 ng/mL phorbol myristic acid (Sigma-Aldrich) and 1,000 ng/mL ionomycin (Sigma-Aldrich) in complete RPMI medium for 5 h at 37°C and then treated with 10 μg/mL brefeldin A (Sigma-Aldrich) for 4 h. Cells were stained for surface molecules, fixed, and permeabilized with Cytofix/Cytoperm (BD Biosciences) and stained for intracellular IFN-γ (XMG1.2) or IL-10 (JES5-16E3). For pSTAT5 staining, tissues were immediately processed in PBS containing 2% paraformaldehyde. Single-cell suspensions were incubated on ice for 20 min, centrifuged, and resuspended in ice-cold methanol for 30 min. Cells were then counted, washed twice in 1% BSA in PBS, and stained with anti-pSTAT5 antibody (47/Stat5 \[pY694\]; BD Biosciences) for 1 h on ice. Data were acquired on a Cyan flow cytometer (DakoCytomation) and analyzed using Summit software (DakoCytomation).

In vitro suppressor assay. {#s7}
--------------------------

Islets were pooled from NOD.BDC.Foxp3^GFP^ mice vaccinated with 2.5 × 10^10^ vector particles (VPs) of AAV8mIP-IL2 or AAV8mIP-EGFP, and single-cell suspensions stained with CD4- and CD3-specific antibodies in PBS supplemented with 2.5% BSA and 2 mmol/L EDTA. CD4^+^CD3^+^GFP^+^ Tregs were sorted on a MoFlo sorter (DakoCytomation). For T cell responders, naive CD4^+^CD62L^+^ splenocytes were isolated from NOD.BDC mice using the CD4^+^CD62L^+^ T cell isolation kit II (Miltenyi Biotec) and labeled with Cell Trace Violet (Invitrogen) as per the manufacturer's recommendations. Cell purity in naive populations was \>95% by flow cytometry. Splenocytes from NOD.Cα^−/−^ mice pulsed with 1 μg/mL sBDC mimetic peptide were used as antigen-presenting cells (APCs). Naive BDC CD4^+^ T cells (2.5 × 10^4^), APCs (2.5 × 10^4^), and varying ratios of Foxp3^+^Tregs were cocultured in complete RPMI medium for 72 h and proliferation of BDC CD4^+^ T cells assessed by dilution of Cell Trace Violet via flow cytometry.

RESULTS {#s8}
=======

β-Cell--expressed IL-2 increases islet Foxp3^+^Tregs. {#s9}
-----------------------------------------------------

To target transgene expression to β-cells, dsAAV8mIP-IL2 encoding IL-2 driven by mIP was engineered. The serotype capsid 8 protein used to package the AAV vector has β-cell--specific tropism ([@B35],[@B36]). IL-2 was detected in cultures of islets prepared from NOD.*scid* mice injected intraperitoneally with dsAAV8mIP-IL2, confirming ectopic IL-2 expression by β-cells in vivo ([Fig. 1*A*](#F1){ref-type="fig"}). No IL-2 was observed in supernatants from single-cell suspensions of liver or heart (data not shown), which are major tissues transduced in vivo by AAV8 vectors ([@B44]). Persistent low levels of IL-2 were detected in the serum of 10--12-week-old NOD female mice treated with dsAAV8mIP-IL2 ([Fig. 1*B*](#F1){ref-type="fig"}). Reduction of β-cell mass by STZ injection prior to dsAAV8mIP-IL2 vaccination significantly decreased serum IL-2 levels ([Fig. 1*C*](#F1){ref-type="fig"}), further indicating ectopic IL-2 expression by β-cells in vivo. No difference in the frequency of conventional CD4^+^ and CD8^+^ T cells, B cells (CD19^+^B220^+^), and NK cells (DX5^+^) was detected in the blood of dsAAV8mIP-IL2--vaccinated animals compared with control groups ([Fig. 1*D*](#F1){ref-type="fig"}).

![In vivo β-cell expression of IL-2 after dsAAV8mIP-IL2 injection. *A*: IL-2 levels in supernatants from islets isolated from NOD.*scid* mice treated with dsAAV8mIP-IL2 or left untreated. \*\**P* \< 0.01, \*\*\**P* \< 0.001, one-way ANOVA ± SEM. *B*: Temporal measurement of serum IL-2 from 10--12-week-old NOD female mice (*n* = 5) treated with dsAAV8mIP-IL2, dsAAV8mIP-EGFP, or left untreated. \*\*\**P* \< 0.001, two-way ANOVA ± SEM. *C*: Serum IL-2 levels in NOD mice (*n* = 5) treated with STZ alone, STZ plus AAV8mIP-IL2 (2.5 × 10^10^ VPs) 72 h later, or AAV8mIP-IL2 (2.5 × 10^10^ VPs) alone at day 10 post--STZ injection. \*\*\**P* \< 0.001, two-way ANOVA ± SEM. *D*: Frequency of immune effector cells in peripheral blood of NOD mice left untreated or treated with dsAAV8mIP-IL2 7, 14, and 21 days later. STZ, streptozotocin.](3775fig1){#F1}

The effect of increased local IL-2 on islet and PLN Foxp3^+^Tregs was examined in 12-week-old NOD female mice 4 weeks after dsAAV8mIP-IL2 treatment. The frequency and number of islet Foxp3^+^Tregs were increased up to two-fold in NOD mice treated with dsAAV8mIP-IL2 compared with animals injected with dsAAV8mIP-EGFP or left untreated ([Fig. 2*A*and *B*](#F2){ref-type="fig"}). Notably, no significant effect on PLN Foxp3^+^Tregs was detected after treatment ([Fig. 2*A*and *B*](#F2){ref-type="fig"}), suggesting that dsAAV8mIP-IL2 administration preferentially affected islet Foxp3^+^Tregs.

![The frequency and number of islet Foxp3^+^Tregs are increased after short-term dsAAV8mIP-IL2 treatment. *A*: CD3^+^CD4^+^ T cells were gated on and the frequency of Foxp3^+^CD25^+^CD4^+^ T cells in the PLNs and islets of groups of 6--10 NOD female mice 4 weeks posttreatment with dsAAV8mIP-IL2, dsAAV8mIP-EGFP, or left untreated. \**P* \< 0.05, \*\**P* \< 10^−2^, \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM. *B*: Number of islet Foxp3^+^CD25^+^CD4^+^ T cells recovered from 70--100 islets/mouse. \**P* \< 0.05, two-way ANOVA ± SEM. Frequency of CD62L^HI^ (*C*) and CD25 mean fluorescence intensity (MFI) (*D*) of Foxp3^+^Tregs in NOD mice from *A*. \**P* \< 0.05, \*\**P* \< 10^−2^, \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM. Frequency of Foxp3^−^CD4^+^ and CD8^+^ T cells (*E*) and the ratio of IFN-γ^+^ Teffs to Foxp3^+^Tregs in the PLN and islets (*F*) of the respective treatment groups. \*\**P* \< 10^−2^, \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM.](3775fig2){#F2}

Phenotypic analyses demonstrated that the frequency of islet CD62L^HI^Foxp3^+^Tregs was significantly increased in dsAAV8mIP-IL2--treated versus control animals ([Fig. 2*C*](#F2){ref-type="fig"}). In addition, the level of CD25 expression by islet Foxp3^+^Tregs, based on mean fluorescence intensity, was elevated in a dsAAV8mIP-IL2 dose-dependent manner ([Fig. 2*A* and *D*](#F2){ref-type="fig"}). In contrast, the frequency of islet Foxp3^+^Treg-expressing CTLA-4, GITR, and ICOS and the levels of expression of the respective molecules were similar between the dsAAV8mIP-IL2 and control groups ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)). Unlike the islets, the phenotype of PLN Foxp3^+^Tregs was unaffected by dsAAV8mIP-IL2 vaccination ([Fig. 2](#F2){ref-type="fig"}).

In contrast to islet Foxp3^+^Tregs, no change in the number of conventional IFN-γ^+^CD4^+^ and CD8^+^ Teffs was detected in the islets of dsAAV8mIP-IL2--treated NOD mice ([Fig. 2*E*](#F2){ref-type="fig"}). However, the ratio between the pool of IFN-γ^+^ Teffs and Foxp3^+^Tregs in the islets but not PLNs was decreased in dsAAV8mIP-IL2 versus untreated and dsAAV8mIP-EGFP cohorts ([Fig. 2*F*](#F2){ref-type="fig"}).

To determine if the increased islet Foxp3^+^Treg pool correlated with elevated IL-2R signaling, levels of pSTAT5 were measured. Up to 50% of islet Foxp3^+^Tregs were pSTAT5^+^, reflecting an ∼10-fold increase in dsAAV8mIP-IL2 versus control groups ([Fig. 3*A*](#F3){ref-type="fig"}). Only a modest two-fold increase in the frequency of pSTAT5^+^ cells was detected in conventional Foxp3^−^CD4^+^ T cells in the islets of NOD mice vaccinated with 2.5 × 10^10^ VPs dsAAV8mIP-IL2 (6.4 ± 1.1%) relative to control animals (3.6 ± 0.6%) ([Fig. 3*B*](#F3){ref-type="fig"}). In contrast, levels of pSTAT5 detected in Foxp3^+^Tregs or Foxp3^−^CD4^+^ T cells in the PLNs were unaffected by β-cell--specific IL-2 ([Fig. 3](#F3){ref-type="fig"}). Together, these findings demonstrate that β-cell--specific IL-2 expression results in an increased pool of phenotypically distinct islet but not PLN Foxp3^+^Tregs marked by elevated IL-2R signaling.

![dsAAV8mIP-IL2 increases the frequency of pSTAT5-expressing islet Foxp3^+^Tregs. CD3^+^CD4^+^ T cells were gated on and the frequency of pSTAT5^+^ islet and PLN Foxp3^+^CD4^+^ (*A*) and Foxp3^−^CD4^+^ (*B*) T cells in 10--12-week-old NOD female mice (*n* = 5) 4 weeks posttreatment with AAV8mIP-IL2 or left untreated determined. \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM.](3775fig3){#F3}

β-Cell--expressed IL-2 enhances the fitness of islet Foxp3^+^Tregs. {#s10}
-------------------------------------------------------------------

Enhanced survival and/or expansion of Foxp3^+^Tregs may explain the increased islet Foxp3^+^Treg pool in dsAAV8mIP-IL2--treated animals. To determine if AAV8mIP-IL2 vaccination increased islet Foxp3^+^Treg survival, expression of the antiapoptotic protein Bcl-2 was measured. The level of Bcl-2-expression following dsAAV8mIP-IL2 treatment was increased in islet Foxp3^+^Tregs ([Fig. 4*A*](#F4){ref-type="fig"}) and a trend toward an elevated frequency of Bcl-2^+^ Foxp3^+^Tregs observed ([Fig. 4*B*](#F4){ref-type="fig"}). In contrast, Bcl-2 expression was unaffected in PLN Foxp3^+^Tregs ([Fig. 4*A* and *B*](#F4){ref-type="fig"}) or in islet IFN-γ^+^CD4^+^ and CD8^+^ Teffs ([Fig. 4*C*](#F4){ref-type="fig"}).

![dsAAV8mIP-IL2 increases expansion and survival of islet Foxp3^+^Tregs. Foxp3^+^CD25^+^CD4^+^ T cells in the PLNs and islets of NOD female mice (*n* = 5) treated with AAV8mIP-IL2 (2.5 × 10^10^ VPs) or left untreated were assessed for the level (*A*) and frequency (*B*) of Bcl-2 expression. \**P* \< 0.05, two-way ANOVA ± SEM. *C*: Bcl-2 expression for IFN-γ^+^CD3^+^CD4^+^ and IFN-γ^+^CD3^+^CD8^+^ Teffs in the PLNs and islets at days 5 and 8 posttreatment with AAV8mIP-IL2 or in untreated NOD mice (*n* = 5). The frequency of KI67^+^Foxp3^+^CD25^+^CD4^+^ T cells (*D*) and KI67^+^ IFN-γ^+^Teffs in the PLN and islets (*E*). \**P* \< 0.05, \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM. *F*: In vitro proliferation of Cell Trace--labeled BDC CD62L^+^CD4^+^ T cells cocultured with peptide-pulsed APCs and various ratios of GFP^+^CD3^+^CD4^+^ T cells isolated from pooled islets of AAV8mIP-IL2 (2.5 × 10^10^ VPs) or AAV8mIP-EGFP--treated (2.5 × 10^10^ VPs) NOD.BDC.Foxp3^GFP^ mice. \*\**P* \< 10^−2^, \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM. MFI, mean fluorescence intensity.](3775fig4){#F4}

Proliferation of islet and PLN Foxp3^+^Tregs after dsAAV8mIP-IL2 administration was analyzed by KI67 staining. The frequency of KI67^+^Foxp3^+^CD25^+^ T cells was significantly increased in the islets by 8 days post--dsAAV8mIP-IL2 treatment ([Fig. 4*D*](#F4){ref-type="fig"}). In contrast, the frequency of KI67^+^Foxp3^+^CD25^+^ T cells in the PLNs remained unchanged over time ([Fig. 4*D*](#F4){ref-type="fig"}), as was the frequency of KI67-staining islet IFN-γ^+^CD4^+^ and CD8^+^ Teffs ([Fig. 4*E*](#F4){ref-type="fig"}).

Next, the influence of β-cell--specific IL-2 on islet Foxp3^+^Treg suppressor activity was assessed. NOD.BDC mice transgenic for a Foxp3--internal ribosome entry site--GFP reporter cassette (NOD.BDC.Foxp3^GFP^) were vaccinated with dsAAV8mIP-IL2 or dsAAV8mIP-EGFP and GFP^+^Foxp3^+^Tregs sorted from the islets 4 weeks later. The capacity of the respective Foxp3^+^Tregs to suppress Cell Trace Violet--labeled naive BDC CD4^+^ T cells following stimulation by peptide-pulsed APC was then measured. Islet Foxp3^+^Tregs from dsAAV8mIP-IL2--treated NOD.BDC.Foxp3^GFP^ mice exhibited significantly increased suppressor activity compared with islet Foxp3^+^Tregs isolated from dsAAV8mIP-EGFP donors at all ratios tested ([Fig. 4*F*](#F4){ref-type="fig"}). Together, these results demonstrate that β-cell--specific IL-2 enhances the fitness of islet Foxp3^+^Tregs characterized by increased Bcl-2 expression, proliferation, and suppressor function.

Type 1 diabetes is prevented at a late preclinical stage in NOD mice by β-cell--expressed IL-2. {#s11}
-----------------------------------------------------------------------------------------------

Since β-cell--specific IL-2 expression increased islet Foxp3^+^Tregs, the efficacy of AAV8mIP-IL2 to suppress ongoing β-cell autoimmunity and prevent overt diabetes was examined. NOD female mice 12 or 16 weeks of age, representing late preclinical stages of type 1 diabetes, received a single intraperitoneal injection of dsAAV8mIP-IL2, dsAAV8mIP-EGFP, or were left untreated, and diabetes was monitored. All NOD female mice treated with 2.5 × 10^10^ VPs of dsAAV8mIP-IL2 at either 12 or 16 weeks of age remained diabetes-free ([Fig. 5*A* and *B*](#F5){ref-type="fig"}). Similarly, the frequency of diabetes was significantly reduced in NOD female mice treated at 12 weeks of age with 1 × 10^10^ VPs of dsAAV8mIP-IL2 (2 of 8) relative to animals left untreated (18 of 22) or receiving 2.5 × 10^10^ VPs dsAAV8mIP-EGFP (10 of 10) ([Fig. 5*A*](#F5){ref-type="fig"}). The latter indicated that diabetes protection was not attributed to a nonspecific effect of dsAAV vector transduction of β-cells.

![dsAAV8mIP-IL2 prevents diabetes in NOD mice at late preclinical stages. *A*: Ten- to 12-week-old NOD female mice were treated with 2.5 × 10^10^ VPs (*n* = 9) or 1 × 10^10^ VPs (*n* = 8) of dsAAV8mIP-IL2, 2.5 × 10^10^ VPs of dsAAV8mIP-EGFP (*n* = 10), or left untreated (*n* = 22) and monitored for diabetes. \**P* \< 0.05, \*\*\**P* \< 10^−3^, Kaplan-Meier log-rank test. *B*: Fifteen- to 16-week-old NOD females were treated with 2.5 × 10^10^ VPs (*n* = 5) dsAAV8mIP-IL2 or were left untreated (*n* = 5) and monitored for diabetes as in *A*. \**P* \< 0.05, Kaplan-Meier log-rank test. *C*: At 35 weeks of age, the frequency of Foxp3^+^CD25^+^CD4^+^ T cells in the islets and PLNs of NOD mice from *A*. \**P* \< 0.05, \*\*\**P* \< 10^−3^, two-way ANOVA ± SEM. *D*: Islet Foxp3^+^CD25^+^CD4^+^ T cells were assessed for CD62L expression. \**P* \< 0.05, \*\*\**P* \< 10^−3^, one-way ANOVA ± SEM. *E*: The ratio of IFN-γ^+^ Teffs to Foxp3^+^Tregs was compared between treatment groups in the PLNs and islets. \**P* \< 0.05, \*\**P* \< 10^−2^, two-way ANOVA ± SEM.](3775fig5){#F5}

Diabetes-free NOD mice at 35 weeks of age exhibited a higher frequency of islet Foxp3^+^Tregs in dsAAV8mIP-IL2 versus control groups, while no marked difference in the PLNs was observed ([Fig. 5*C*](#F5){ref-type="fig"}). Furthermore, islet Foxp3^+^Tregs of dsAAV8mIP-IL2--treated NOD mice were characterized by an increased frequency of CD62L^HI^ Foxp3^+^Tregs ([Fig. 5*D*](#F5){ref-type="fig"}). Additionally, the ratio of IFN-γ^+^ Teffs to Foxp3^+^Tregs was decreased in the islets of dsAAV8mIP-IL2--treated NOD mice compared with normoglycemic untreated controls ([Fig. 5*E*](#F5){ref-type="fig"}). No difference, however, was detected in the IFN-γ^+^ Teffs to Foxp3^+^Tregs ratio for PLN of dsAAV8mIP-IL2--vaccinated animals ([Fig. 5*E*](#F5){ref-type="fig"}). These results demonstrate that β-cell--specific IL-2 expression effectively suppresses ongoing autoimmunity long-term by enhancing the islet Foxp3^+^Treg pool.

DISCUSSION {#s12}
==========

IL-2 is essential for the homeostasis of Foxp3^+^Tregs, and dysregulation of the IL-2--IL-2R axis has been linked to aberrant Foxp3^+^Treg survival and/or function in NOD mice and type 1 diabetic patients ([@B9]--[@B12]). Systemic administration of low-dose rIL-2 or IL-2--antibody complexes is effective in preventing ongoing β-cell autoimmunity in NOD mice ([@B16],[@B25]--[@B29]). Nevertheless, achieving a protective versus proinflammatory response via systemic rIL-2 delivery can be problematic. For instance, systemic low-dose rIL-2 plus rapamycin resulted only in a transient increase in FOXP3^+^Tregs in type 1 diabetic subjects, and β-cell function declined, suggesting exacerbated autoimmunity ([@B30]). Our results demonstrate that dsAAV vector--mediated targeting of IL-2 expression to β-cells is an effective strategy to manipulate the islet Foxp3^+^Treg pool and diabetogenic response, while avoiding complications associated with systemic delivery of rIL-2.

A key finding made in this study was the differential effect of β-cell--specific IL-2 on islet-infiltrating Foxp3^+^Tregs and Teffs ([Fig. 2](#F2){ref-type="fig"}). Elevated local levels of IL-2 resulted in marked expansion of islet Foxp3^+^Tregs but not Teffs. This observation is consistent with studies demonstrating that Foxp3^+^Tregs are more sensitive to IL-2 compared with naive T cells and Teffs, partly due to constitutive expression of CD25 by Foxp3^+^Tregs ([@B45]). Indeed, the level and frequency of IL-2R signaling as measured by pSTAT5 was significantly increased in islet Foxp3^+^Tregs versus Teffs in dsAAV8mIP-IL2--treated NOD mice ([Fig. 3](#F3){ref-type="fig"}). No effect of β-cell--specific IL-2 expression on PLN-resident Foxp3^+^Tregs was detected ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}), presumably due to β-cell secretion of low levels of IL-2 into the bloodstream and not the lymphatics. The increased number of islet Foxp3^+^Tregs correlated with enhanced proliferation early after dsAAV8mIP-IL2 treatment ([Fig. 4*D*](#F4){ref-type="fig"}). Interestingly, islet Foxp3^+^Tregs division was reduced compared with untreated animals 4 weeks post--dsAAV8mIP-IL2 vaccination ([Fig. 4*D*](#F4){ref-type="fig"}). This result suggests that homeostasis is achieved overtime within the Foxp3^+^Treg pool despite increased local levels of IL-2 and elevated IL-2R signaling ([Fig. 3](#F3){ref-type="fig"}). Accordingly, long-term maintenance of islet Foxp3^+^Tregs in dsAAV8mIP-IL2--treated animals ([Fig. 5*C*and *D*](#F5){ref-type="fig"}) is likely due to enhanced survival, reflected by increased expression of anti-apoptotic Bcl-2 ([Fig. 4*A*](#F4){ref-type="fig"}) and Bcl-xL ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)) as opposed to persistent levels of elevated Foxp3^+^Treg proliferation in the islets.

In addition to increasing the size of the pool, β-cell--specific IL-2 also induced qualitative changes in islet Foxp3^+^Tregs. For instance, up to a four-fold increase in suppressor activity was detected in vitro by BDC peptide--specific islet Foxp3^+^Tregs from dsAAV8mIP-IL2--treated NOD.BDC.Foxp3^GFP^ mice ([Fig. 4*F*](#F4){ref-type="fig"}). The latter may be explained by the approximate two-fold increase in the frequency of CD62L^HI^ Foxp3^+^Tregs in the islets of dsAAV8mIP-IL2--treated NOD mice ([Fig. 2*C*](#F2){ref-type="fig"}). We and others ([@B6],[@B19],[@B46],[@B47]) have reported that CD62L^HI^ versus CD62L^LO^ Foxp3^+^Tregs exhibit increased suppressor activity and that elevated systemic levels of IL-2 promote expansion of CD62L^HI^ Foxp3^+^Tregs in vivo. An increase in the general fitness of islet Foxp3^+^Tregs, marked by elevated levels of CD25 and anti-apoptotic molecules for instance, may also contribute to more robust suppressor function. Enhanced islet Foxp3^+^Treg suppression, however, did not correlate with elevated levels of IL-10 or transforming growth factor-β1 expression (data not shown).

Importantly, increases in islet Foxp3^+^Tregs by β-cell--expressed IL-2 were sufficient to suppress ongoing β-cell autoimmunity at late preclinical stages and prevent the onset of diabetes long-term ([Fig. 5*A*and *B*](#F5){ref-type="fig"}). Initial efforts to induce remission in recent-onset diabetic NOD mice by dsAAV8mIP-IL2 vaccination have proven to be unsuccessful ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)). The latter may be due to an insufficient β-cell pool that can be transduced, thereby limiting local levels of IL-2 ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)). It is noteworthy that the reduced ratio of Teffs to Foxp3^+^Tregs and increased frequency of CD62L^HI^ Foxp3^+^Tregs in the islets observed 4 weeks post--dsAAV8mIP-IL2 vaccination ([Fig. 2](#F2){ref-type="fig"}) were also evident in NOD mice monitored for diabetes long-term (e.g., up to 23 weeks after dsAAV vaccination) ([Fig. 5](#F5){ref-type="fig"}). This result is particularly striking in view of the progressive increase in the Teffs to Foxp3^+^Tregs ratio, as well as the declining frequency of CD62L^HI^ Foxp3^+^Tregs apparent in the islets of 35-week-old control NOD female mice ([Fig. 5*D*and *E*](#F5){ref-type="fig"}), typical of ongoing β-cell autoimmunity. These findings demonstrate that once established, the islet Foxp3^+^Treg pool is maintained long-term by persistent β-cell--expressed IL-2. Indeed, similar numbers of islet Foxp3^+^Tregs were detected in NOD mice treated 23 ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)) versus 4 weeks ([Fig. 2*B*](#F2){ref-type="fig"}) post--dsAAVmIP-IL2 vaccination. Whether expression of β-cell--specific IL-2 is required to maintain islet Foxp3^+^Tregs needs to be determined. Interestingly, dsAAV8mIP-IL2 failed to prevent diabetes in transgenic NOD.8.3 mice expressing the H2K^d^-restricted T-cell receptor specific for islet-specific glucose-6-phosphatase catalytic subunit-related protein ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)), suggesting that Foxp3^+^Tregs are required for disease prevention; for instance, CD4^+^ Foxp3^+^Tregs make up only \<1% of the islet T cell pool following dsAAV8mIP-IL2 vaccination.

This study further highlights the efficacy of dsAAV vector--mediated gene transfer to selectively modify the immunogenicity of β-cells in vivo. Transduction of β-cells in vivo with a dsAAV vector results in rapid transgene expression that persists long-term ([Fig. 1*B*](#F1){ref-type="fig"}); the latter indirectly demonstrating that β-cell viability and function are unaffected by dsAAV vector transduction. The use of an insulin promoter restricts transgene expression to β-cells, so that high local cytokine levels can be obtained within the islets and complications associated with systemic cytokine delivery minimized ([@B30]). A similar approach has been taken to target ectopic IL-4 expression to β-cells ([@B35]). Recent technological advances can also be exploited to refine β-cell specificity and reduce immunogenicity of AAV capsid proteins, thereby enhancing application of dsAAV vector gene transfer for the treatment of type 1 diabetes in the clinic ([@B48]).

Our observations are consistent with a model in which elevated local IL-2 has direct effects on islet Foxp3^+^Tregs, only minimal (if any) on islet Teffs, and no effect on non--T cell islet residents such as NK cells and B cells ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1)). An increased pool of islet Foxp3^+^Tregs characterized by a phenotypic shift toward CD62L^HI^ Foxp3^+^Tregs and increased fitness and suppressor function effectively blocks ongoing β-cell destruction by Teffs. Once established, the islet Foxp3^+^Treg pool is stable and long-term tolerance maintained. These results provide strong rationale to further pursue β-cell--specific targeting of IL-2 and other cytokines as a strategy to manipulate islet-resident Tregs and block the diabetogenic response.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0669/-/DC1>.
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